Skip to main content
رجوع
Watch Compare

Sigyn Therapeutics, Inc.

جودة البيانات: 83%
SIGY
OTC Manufacturing Measuring & Analyzing Instruments
KWD 0.03
▲ KWD 0.01 (36.00%)
القيمة السوقية: 54,582.0
السعر
KWD 0.03
القيمة السوقية
54,582.0
نطاق اليوم
KWD 0.02 — KWD 0.03
نطاق 52 أسبوعًا
KWD 0.01 — KWD 5.00
حجم التداول
111,291
فتح KWD 0.03
متوسط 50 يوم / 200 يوم
KWD 0.29
88.35% below
متوسط 50 يوم / 200 يوم
KWD 1.93
98.24% below

Quick Summary

النقاط الرئيسية

Negative free cash flow of -936,426.0

النمو

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

الجودة

Return on Equity
N/A
ROICN/A
Net MarginN/A
Op. MarginN/A

الأمان

Debt / Equity
N/A
Current Ratio0.02
Interest CoverageN/A

التقييم

PE (TTM)
-0.02
أعلى من متوسط القطاع (-1.48)
P/B RatioN/A
EV/EBITDAN/A
Dividend YieldN/A

تاريخ السعر

الاتجاهات المالية

مقارنة الأقران

مقابل وسيط قطاع Manufacturing (1364 نظير)
المقياس السهم وسيط القطاع
P/E 0.0 -1.5
P/B — 1.6
ROE % — -53.4
Net Margin % — -41.5
Rev Growth 5Y % — 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) N/A Net Income (TTM) -3.22 M
ROE N/A ROA -3438.93%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -936,426.0
ROIC N/A FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.02
Interest Coverage N/A Asset Turnover N/A
Working Capital -3.90 M Tangible Book Value -5.92 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -0.02 Forward P/E N/A
P/B Ratio N/A P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -1715.63%
Market Cap 54,582.0 Enterprise Value 3.82 M
Per Share
EPS (Diluted TTM) -1.93 Revenue / Share N/A
FCF / Share -0.58 OCF / Share -0.58
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 29.07%
SBC-Adj. FCF -1.12 M Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue — — — — —
Net Income -3.34 M -4.15 M -2.93 M -3.00 M -1.26 M
EPS (Diluted) -2.51 -3.77 — — —
Gross Profit — — — — —
Operating Income -2.52 M -2.46 M -2.15 M -2.01 M -916,434.0
EBITDA — — — — —
R&D Expenses 773,279.0 798,165.0 657,657.0 734,014.0 27,456.0
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — — 30,800.0 30,800.0 343,156.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 213,719.0 321,806.0 332,879.0 710,259.0 694,082.0
Total Liabilities 4.67 M 3.73 M 2.24 M 974,843.0 594,903.0
Shareholders' Equity -4.46 M -3.41 M -1.90 M -264,584.0 99,179.0
Total Debt 2.20 M 2.51 M 2.28 M — —
Cash & Equivalents 12,144.0 11,690.0 8,356.0 340,956.0 84,402.0
Current Assets 21,244.0 118,063.0 70,298.0 393,031.0 670,449.0
Current Liabilities 4.61 M 3.61 M 2.05 M 734,218.0 594,903.0